Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SunRISe-2: TAR-200 + cetrelimab versus concurrent chemoradiotherapy for muscle-invasive bladder cancer
2023-507188-21-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of gemcitabine-releasing intravesical system and cetrelimab in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Bladder-intact event-free survival. Planned start Apr 2021; status: authorised.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2023-507188-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507188-21-00.